Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Paroxetine

Paroxetine

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) medication used to treat depression, anxiety disorders, and other mental health conditions.
It works by increasing the availability of the neurotransmitter serotonin in the brain, which can help to improve mood and reduce symptoms.
Paroxetine is generally well-tolerated, but like other medications, it may have side effects such as nausea, dry mouth, and sleepiness.
It is important to work closely with a healthcare provider when taking paroxetine to ensure the dosage is appropriate and that any potential side effects are managed effectively.
The PubCompare.ai platform can help researchers optimize their paroxetine research by identifying the most reproducible and accurate protocols from the literature, preprints, and patents, streamlining the research process and enhancing the quality of the work.

Most cited protocols related to «Paroxetine»

1
Systematic Review of Antidepressant Treatments
We did a systematic review and network meta-analysis. We searched the Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS database, MEDLINE, MEDLINE In-Process, PsycINFO, AMED, the UK National Research Register, and PSYNDEX from the date of their inception to Jan 8, 2016, with no language restrictions. We used the search terms “depress*” OR “dysthymi*” OR “adjustment disorder*” OR “mood disorder*” OR “affective disorder” OR “affective symptoms” combined with a list of all included antidepressants.
We included double-blind, randomised controlled trials (RCTs) comparing antidepressants with placebo or another active antidepressant as oral monotherapy for the acute treatment of adults (≥18 years old and of both sexes) with a primary diagnosis of major depressive disorder according to standard operationalised diagnostic criteria (Feighner criteria, Research Diagnostic Criteria, DSM-III, DSM-III-R, DSM-IV, DSM-5, and ICD-10). We considered only double-blind trials because we included placebo in the network meta-analysis, and because this study design increases methodological rigour by minimising performance and ascertainment biases.7 (link) Additionally, we included all second-generation antidepressants approved by the regulatory agencies in the USA, Europe, or Japan: agomelatine, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, venlafaxine, vilazodone, and vortioxetine. To inform clinical practice globally, we selected the two tricyclics (amitriptyline and clomipramine) included in the WHO Model List of Essential Medicines). We also included trazodone and nefazodone, because of their distinct effect and tolerability profiles. Additionally, we included trials that allowed rescue medications so long as they were equally provided among the randomised groups. We included data only for drugs within the therapeutic range (appendix pp 133, 134). Finally, we excluded quasi-randomised trials and trials that were incomplete or included 20% or more of participants with bipolar disorder, psychotic depression, or treatment-resistant depression; or patients with a serious concomitant medical illness.
The electronic database searches were supplemented with manual searches for published, unpublished, and ongoing RCTs in international trial registers, websites of drug approval agencies, and key scientific journals in the field.8 For example, we searched ClinicalTrials.gov using the search term “major depressive disorder” combined with a list of all included antidepressants. We contacted all the pharmaceutical companies marketing antidepressants and asked for supplemental unpublished information about both premarketing and post-marketing studies, with a specific focus on second-generation antidepressants. We also contacted study authors and drug manufacturers to supplement incomplete reports of the original papers or provide data for unpublished studies.
Six pairs of investigators (ACi, TAF, LZA, SL, HGR, YO, NT, YH, EHT, HI, KS, and AT) independently selected the studies, reviewed the main reports and supplementary materials, extracted the relevant information from the included trials, and assessed the risk of bias. Any discrepancies were resolved by consensus and arbitration by a panel of investigators within the review team (ACi, TAF, LZA, EHT, and JRG).
The full protocol of this network meta-analysis has been published.8
Cipriani A., Furukawa T.A., Salanti G., Chaimani A., Atkinson L.Z., Ogawa Y., Leucht S., Ruhe H.G., Turner E.H., Higgins J.P., Egger M., Takeshima N., Hayasaka Y., Imai H., Shinohara K., Tajika A., Ioannidis J.P, & Geddes J.R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet (London, England), 391(10128), 1357-1366.
Publication 2018
Adjustment Disorders Adult Affective Symptoms agomelatine Amitriptyline Antidepressive Agents Antidepressive Agents, Second-Generation Bipolar Disorder Bupropion Citalopram Clomipramine Depressive Disorder, Treatment-Resistant Desvenlafaxine Diagnosis Dietary Supplements Drugs, Essential Duloxetine Escitalopram Fluoxetine Fluvoxamine Gender Levomilnacipran Major Depressive Disorder Mental Disorders Milnacipran Mirtazapine Mood Disorders Muscle Rigidity nefazodone Paroxetine Patients Pharmaceutical Preparations Placebos Reboxetine Sertraline Syringa Therapeutics Trazodone Tricyclic Antidepressive Agents Venlafaxine Vilazodone Vortioxetine
2
Ligand Binding and Uptake Assays for SERT
Ligand binding experiments were carried out by adding HEK293 membranes containing SERT to a final concentration of 2 nM in 1 ml of TBS with either [3H]paroxetine 0.01–10 nM or [3H](R/S)-citalopram 0.01–20 nM. Reactions were rotated at room temperature for 4 hours followed by filtering through a glass microfiber filter prewet with 0.4% polyethylenimine in TBS. Membranes were washed 3x with 4 ml of TBS followed by liquid scintillation counting. Data was fit to a single-site binding curve accounting for ligand depletion. For dissociation, 20 nM SERT in membranes was mixed with 40 nM [3H](R/S)-citalopram in 10 μl; samples were diluted to 1 ml in TBS with 100 μM (S)-citalopram, or without ligand, followed by filtering. For uptake assays, ~105 HEK293 cells in 96-well Cytostar T plates were transfected with 0.2 μg of plasmid with Polyjet. After 24–36 hrs, cells were washed with 25 mM HEPES-Tris pH 7.0, 130 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 1 mM ascorbic acid, and 5 mM glucose. For a control, 10 μM paroxetine was added. [14C]5-hydroxytryptamine at concentrations of 0.02–40 μM was added and uptake was followed using a MicroBeta scintillation counter. Data was fit to a Michaelis-Menten equation.
Coleman J.A., Green E.M, & Gouaux E. (2016). X-ray structures and mechanism of the human serotonin transporter. Nature, 532(7599), 334-339.
Publication 2016
Ascorbic Acid Binding Sites Biological Assay Cells Citalopram Escitalopram Glucose HEK293 Cells HEPES Ligands Paroxetine Plasmids Polyethyleneimine Scintillation Counters Serotonin Sodium Chloride Sulfate, Magnesium Tissue, Membrane Tromethamine
3
Ligand Binding and Uptake Assays for SERT
Ligand binding experiments were carried out by adding HEK293 membranes containing SERT to a final concentration of 2 nM in 1 ml of TBS with either [3H]paroxetine 0.01–10 nM or [3H](R/S)-citalopram 0.01–20 nM. Reactions were rotated at room temperature for 4 hours followed by filtering through a glass microfiber filter prewet with 0.4% polyethylenimine in TBS. Membranes were washed 3x with 4 ml of TBS followed by liquid scintillation counting. Data was fit to a single-site binding curve accounting for ligand depletion. For dissociation, 20 nM SERT in membranes was mixed with 40 nM [3H](R/S)-citalopram in 10 μl; samples were diluted to 1 ml in TBS with 100 μM (S)-citalopram, or without ligand, followed by filtering. For uptake assays, ~105 HEK293 cells in 96-well Cytostar T plates were transfected with 0.2 μg of plasmid with Polyjet. After 24–36 hrs, cells were washed with 25 mM HEPES-Tris pH 7.0, 130 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 1 mM ascorbic acid, and 5 mM glucose. For a control, 10 μM paroxetine was added. [14C]5-hydroxytryptamine at concentrations of 0.02–40 μM was added and uptake was followed using a MicroBeta scintillation counter. Data was fit to a Michaelis-Menten equation.
Coleman J.A., Green E.M, & Gouaux E. (2016). X-ray structures and mechanism of the human serotonin transporter. Nature, 532(7599), 334-339.
Publication 2016
Ascorbic Acid Binding Sites Biological Assay Cells Citalopram Escitalopram Glucose HEK293 Cells HEPES Ligands Paroxetine Plasmids Polyethyleneimine Scintillation Counters Serotonin Sodium Chloride Sulfate, Magnesium Tissue, Membrane Tromethamine
4
Pooled Depression Treatment Protocols
The sample consisted of participants from the ADM and pill-placebo conditions of five MDD trials: Elkin et al.14 (link), DeRubeis et al.12 (link), Dimidjian et al.13 (link), Philipp et al.15 (link), Wichers et al.16 (link), and one Minor Depression trial, Barrett et al.11 (link) Full descriptions of the study designs, sample characteristics, treatment protocols, and primary outcome findings have been reported elsewhere.11 (link)–16 (link) Three studies utilized the tricyclic antidepressant (TCA) imipramine14 (link)–16 (link) and three utilized the selective serotonin reuptake inhibitor (SSRI) paroxetine.11 (link)–13 (link)Table 1 lists characteristics that differ among the six studies. The pooled sample used in the current analyses included 434 patients in the ADM group and 284 patients in the placebo group. Individual baseline HRSD depression severity levels ranged from 10 to 39. In comparison to the 20 identified studies for which data were not available, the 6 included studies tended to have Jadad quality scores at the higher end of the range, to use flexible (as opposed to fixed) medication doses, and to provide more information about the samples in the original report (see Supplemental Table).
Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C, & Fawcett J. (2010). Antidepressant Drug effects and Depression Severity: A Patient-Level Meta-Analysis. JAMA : the journal of the American Medical Association, 303(1), 47-53.
Publication 2010
Contraceptives, Oral Paroxetine Patients Pharmaceutical Preparations Placebos Selective Serotonin Reuptake Inhibitors Training Programs Treatment Protocols Tricyclic Antidepressive Agents
5
Purification and Crystallization of SERT-Fab Complex
The hSERT constructs were expressed as C-terminal GFP fusions using baculovirus-mediated transduction of mammalian HEK-293S GnTI− cells, as previously described25 (link),52 (link). Cells were subsequently solubilized in 50 mM Tris pH 8, 150 mM NaCl containing 20 mM DDM, 2.5 mM cholesteryl hemisuccinate (CHS), 0.5 mM dithiothreitol (DTT) in the presence of 1 μM inhibitor (paroxetine, (S)-citalopram, or Br-citalopram). The lysate was passed over 10 ml of Strep Tactin resin, washed with 18 column volumes of 1 mM DDM, 0.2 mM CHS, 5% glycerol, 25 μM lipid (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine, and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol at a molar ratio of 1:1:1), and 1 μM ligand in TBS. SERT was eluted in the same buffer containing 5 mM desthiobiotin. The N- and C-terminus containing GFP and purification tags were removed by thrombin digestion and N-linked sugars were truncated using EndoH. SERT was mixed with recombinant 8B6 Fab at a 1:1.2 molar ratio. In the case of Br-citalopram complexed at the central site, Fab purified from hybridoma cells was used. The resulting complexes were further purified by size exclusion chromatography in TBS supplemented with 40 mM n-octyl β-D-maltoside, 0.5 mM CHS, 5% glycerol, 25 μM lipid, and 1 μM inhibitor. The purified SERT-8B6 complex was concentrated to 2 mg/ml−1 and the transporter solution was spiked with 10 μM inhibitor and 1 μM 8B6 Fab, final concentrations, immediately prior to crystallization.
Coleman J.A., Green E.M, & Gouaux E. (2016). X-ray structures and mechanism of the human serotonin transporter. Nature, 532(7599), 334-339.
Publication 2016
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine 1-palmitoyl-2-oleoylglycero-3-phosphoglycerol 1-palmitoyl-2-oleoylphosphatidylcholine Baculoviridae Buffers Cells cholesterol-hemisuccinate Citalopram Crystallization desthiobiotin Digestion Dithiothreitol Escitalopram Glycerin Hybridomas Ligands Lipids Mammals Membrane Transport Proteins Molar Molecular Sieve Chromatography Paroxetine Resins, Plant Sodium Chloride Streptococcal Infections Sugars Thrombin Tromethamine

Most recents protocols related to «Paroxetine»

1
Shame and Guilt in Obsessive-Compulsive Disorder
A total of 62 participants (38 women and 24 men) were examined in this study. Of these, 31 patients fulfilled the criteria of OCD [ICD-10 F42.X: mean age 35.2 (SD = 10.7) years] and 31 subjects formed the healthy control group [mean age 39.1 (SD = 15.0) years]. A detailed description of the groups can be found in Table 1.

Sociodemographic and clinical characteristics

TraitOCDN = 31HCN = 31p-value*
Age, mean (SD), years38,7 (11,9)39,6 (13,1)n. s
Gender
 Female n,19 (61,3%)19 (61,3%)n. s
 Male n,12 (38,7%)12 (38,7%)
Marital status
 Single, n17 (54,8%)12(38,7%)
 Married, n9 (29,0%)19 (61,3%)p = 0.009
 Divorced, n5 (16,1%)0
Current Partnership
 - No13 (41,9%)7 (22,6%)n. s
 - Yes18 (58,1%)24 (77,4%)
Graduation
 High school, n25 (80,7%)24 (77,4)
 Junior high school, n3 (9,7%)5 (16,1%)n. s
 Low school., n3 (9,7%)2 (6,5%)
Occupational status

 Current employment

(Including be a student), n

22 (71,0%)27 (87,1%)n. s
  No current Job,9 (29,0%)4 (12,9%)
Diagnosis (ICD-10)
 F42.0, n5 (16,1%)/
 F42.2, n26 (83,9%)
Age of onset
 mean (SD), years23,2 (9,1)/
Duration of illness
 mean (SD), years15,8 (10,8)/

*x2-Test/ t-Test; n. s. non-significant, OCD Obsessive–compulsive disorder, HC Healthy controls

All OCD patients were recruited and examined during their treatment at the Department of Psychiatry (LWL-University Hospital of the Medical Faculty of Ruhr-University Bochum, special outpatient clinic for OCDs). Examination of the healthy volunteers also took place at the LWL-University Hospital Bochum and recruitment was via notices and flyers.
Patients and healthy volunteers aged 18–67 years were included. Further inclusion criteria were a verbal IQ > 70, sufficient German language skills and the ability to give informed consent according to the Helsinki and ICH-GCP declarations. Exclusion criteria for the study were: severe somatic diseases; other mental diseases, such as reduced intelligence (ICD10 F70–F70.9), schizophrenia (ICD10 F20–F20.9) or organic brain disorders (ICD10 F06–F06.9, dependence on illegal drugs); acute suicidal tendencies or behaviour endangering others; and lack of informed consent to participate in the study.
Furthermore, psychopharmacotherapy was not an exclusion criterion for patients with OCD. In this respect, 96.8% of the patients (n = 30) received monotherapy, whereby antidepressants from the selective serotonin reuptake inhibitor group [e.g. sertraline (n = 21), escitalopram, paroxetine, fluoxetine] but also clomipramine (a tricyclic antidepressant) were predominantly used. Moreover, seven of the patients received a combination treatment (mainly a sedating antipsychotic medication, e.g. promethazine or quetiapine). At the time of inclusion in the study, 12 patients were receiving psychotherapeutic treatment (validation therapy: n = 9; deep psychology: n = 3). Only five of the patients (16.1%) with OCD had not received psychotherapy at the time of study inclusion, either currently or in the past. A detailed anamnesis was taken from all OCD patients and healthy volunteers in a semi-structured interview (duration 45–60 min). The psychometric characteristics, including shame and guilty proneness, were gathered using various questionnaires.
The study was approved by the local Ethics Committee (No. 20–6883) of the Medical Faculty of Ruhr-University Bochum.
Mavrogiorgou P., Becker S., Lee-Grimm S.I, & Juckel G. (2023). Embitterment and metacognition in obsessive–compulsive disorder. BMC Psychiatry, 23, 146.
Publication 2023
Antidepressive Agents Antipsychotic Agents Brain Diseases Clomipramine Diagnosis Diploid Cell Drug Dependence Escitalopram Faculty, Medical Fluoxetine Guilt Healthy Volunteers Immunologic Memory Males Paroxetine Patients Promethazine Psychometrics Psychotherapy Psychotic Disorders Psychotropic Drugs Quetiapine Regional Ethics Committees Schizophrenia Selective Serotonin Reuptake Inhibitors Sertraline Shame Student Therapeutics Tricyclic Antidepressive Agents Woman
2
Mirtazapine vs. Vortioxetine for Treatment-Resistant Depression
Inclusion criteria for GP practices were: (a) up to one GP/practice participating at any time; located within one of the study’s South East London areas; and (b) using EMIS electronic health record software. Inclusion criteria for patients in addition to being registered at one of the participating practices were: (a) age ≥18, (b) at least moderately severe major depressive syndrome on Patient Health Questionnaire (PHQ-9; a score of ≥15),8 (link) (c) no plans to change GP practice, (d) able to complete self-report scales orally or in writing, (e) no previous prescription of mirtazapine or vortioxetine, (f) evidence of early treatment resistance as defined by (i) current or recent prescription (in the last 2 months) of any of the following antidepressants listed: citalopram, fluoxetine, sertraline, escitalopram, paroxetine, venlafaxine or duloxetine, and (ii) previous prescription of at least one other antidepressant out of the same list of antidepressants.
Exclusion criteria for patients were: (a) inability to consent to the study, (b) unstable medical condition (assessed based on in-depth screening visit), (c) currently being treated by mental health specialist, (d) high suicide risk (assessed with Mini International Neuropsychiatric Interview suicidality screen),9 (e) past diagnosis of schizophrenia or schizo-affective disorder, (f) current psychotic symptoms (three clinical screening questions validated in our previous work to exclude schizophreniform disorders),10 11 (link) (g) bipolar disorder on WHO Composite International Diagnostic Interview12 (link) at prescreening or using the Structured Clinical Interview for DSM-513 at screening including Bipolar Otherwise Specified categories, (h) currently at risk of being violent (assessed on in-depth screening visit), (i) drug (modified PHQ) or alcohol abuse (PHQ)8 (link) over the last 6 months, (j) suspected central neurological condition (eg, dementia, stroke, assessed on in-depth screening visit), (k) (planned) pregnancy or insufficient contraception in women of childbearing age (assessed on in-depth screening visit and prescreening), (l) breast feeding or within 6 months of giving birth, (m) has already been prescribed both escitalopram and sertraline.
Harrison P., Carr E., Goldsmith K., Young A., Ashworth M., Fennema D., Duan S., Barrett B.M, & Zahn R. (2023). Antidepressant Advisor (ADeSS): a decision support system for antidepressant treatment for depression in UK primary care – a feasibility study. BMJ Open, 13(3), e060516.
Publication 2023
Abuse, Alcohol Antidepressive Agents Bipolar Disorder Cerebrovascular Accident Childbirth Citalopram Contraceptive Methods Dementia Diagnosis Duloxetine Escitalopram Fluoxetine Mental Disorders Mental Health Mirtazapine Nervous System Disorder Paroxetine Patients Pharmaceutical Preparations Pregnancy Schizoaffective Disorder Schizophrenia Schizophreniform Disorders Sertraline Syndrome Venlafaxine Vortioxetine Woman
3
Medication Patterns in Mental Health
Patients with drug treatments were allocated into four categories as follows: with antidepressants, with antipsychotics, switching medication, and combined medication. In Group A (6-month follow-up group), 63 patients were treated with medications, with 42 of these patients with antidepressants, 5 patients with antipsychotics, 5 patients with switching medication, and 11 patients with combined medication. In Group B (12-month follow-up group), 25 patients were treated with medications, with 17 of these patients with antidepressants, 2 patients with antipsychotics, 4 patients with switching medication, and 2 patients with combined medication. The choice of antidepressants included four SSRI, i.e., fluoxetine, paroxetine, escitalopram, and sertraline, and one noradrenergic and specific serotonergic antidepressant (NaSSA), i.e., mirtazapine. There was a single choice of antipsychotic medication: sulpiride.
Chiu H.P., Huang M.W., Tsai S.Y, & Hsu C.Y. (2023). A retrospective study of pharmacological treatment in anorexia nervosa: 6-month and 12-month follow-up. BMC Psychiatry, 23, 126.
Publication 2023
Antidepressive Agents Antipsychotic Agents Escitalopram Fluoxetine Mirtazapine Paroxetine Patients Pharmaceutical Preparations Sertraline Sulpiride
4
COVID-19 Patients' Psychiatric Drug Intervention
The National Exhibition and Convention Centre of Shanghai Fangcang Shelter Hospital were constructed as a temporary medical building for the admission and hospitalisation of infected patients with moderate and mild COVID-19 symptoms. It received 174,308 infected patients from 9 April 2022 to 31 May 2022. The infected patients were cured to discharge or transferred to a designated hospital for treatment with severe symptoms. The information of infected patients who used the drugs as listed (risperidone, olanzapine, quetiapine, paroxetine, sertraline, venlafaxine, flupentixol-melitracen, escitalopram oxalate, zolpidem tartrate, estazolam) was collected as the drug intervention group. Patients diagnosed of schizophrenia were mainly prescribed with risperidone, olanzapine and quetiapine. For depression diagnosis, patients were prescribed with paroxetine, sertraline, venlafaxine, flupentixol-melitracen or escitalopram oxalate according their individual specific symptom. Patients with insomnia were prescribed with zolpidem. And patients with symptoms of anxiety or sleep disorders were intervened with estazolam. The information was integrated when the infected individual used different drugs were classified listed as schizophrenia, depression, insomnia, anxiety or sleep disorder according to the symptom severity from severe to mild. A total of 6,218 individuals treated with the list drugs in the Fangcang shelter hospital were processed. Simultaneously, information of a corresponding comparable control group of 30,000 infected patients who has no listed psychiatric drug intervention was randomly drawn out based on the number of patients in the drug intervention group.
Yu P., Bian X., Xie Z., Wang X., Zhang X., Gu Z., Yang Z., Jing F., Qiu W., Lin J., Tang J., Huang C., Zhang Y., Chen Y., Zhang Z., Bi Y., Shang H, & Chen E. (2023). Risk factor analysis of omicron patients with mental health problems in the Fangcang shelter hospital based on psychiatric drug intervention during the COVID-19 pandemic in Shanghai, China. Frontiers in Psychiatry, 14, 1100849.
Publication 2023
A 218 Anxiety Conferences COVID 19 Diagnosis Escitalopram Oxalate Estazolam flupentixol, melitracen drug combination Olanzapine Paroxetine Patient Discharge Patients Pharmaceutical Preparations Quetiapine Risperidone Schizophrenia Sertraline Sleep Disorders Sleeplessness Venlafaxine Zolpidem Zolpidem Tartrate
5
Zebrafish Exposed to SSRI Medications
Long-term exposures. For long-term exposure experiments, 5 dpf juvenile zebrafish were exposed to Fluoxetine, Paroxetine, or Sertraline at 10, 100 or 200 μg/L, based on previously published work [21 (link),29 (link),30 (link),31 (link),32 (link),33 (link)], for a total of 135 days.
Mixtures of all three SSRIs at equal concentrations that, when combined, added up to 10, 100, or 200 µg/L were also tested. Since Sertraline working stocks were made in DMSO, the resulting 10, 100, and 200 µg/L Sertraline exposures contained negligible concentrations of DMSO (0.0001, 0.001, and 0.002 % (v/v), respectively) and the resulting 10, 100, and 200 µg/L SSRI mixture exposures also contained negligible concentrations of DMSO (0.000033, 0.0003, and 0.0006% (v/v), respectively).
Each tank contained up to 50 fish from 5–30 dpf or up to 15 fish from 30–170 dpf. There were three replicate tanks for each exposure group along with a separate tank for controls. Controls were not exposed to SSRIs but were housed in otherwise identical conditions. Water was renewed every 5 days with working stocks of SSRIs pipetted directly into a new tank containing 2 L of clean water. An additional 400 mL of clean water was then added to the tank to ensure proper mixing of the drug. Fish were then transferred by netting to a new exposure tank. Exposures were followed by a 2-week washout period before a second breeding assessment was carried out for another 2 weeks (Figure 1a). Fish were euthanized at the conclusion of the study.
Short-term exposures. For short-term experiments, adult fish (10–14 months old) were exposed to the same SSRIs as for the long-term experiments or their combination at 10 μg/L for 3 weeks and breeding was assessed for 2 weeks (35 day exposure). This was followed by a 2-week washout period before a second breeding assessment was carried out for another 2 weeks (Figure 1b). Each exposure group had three replicate tanks along with a control (untreated) group; each tank contained 20 fish. Fish were euthanized at the conclusion of the study.
Venkatachalam A.B., Levesque B., Achenbach J.C., Pappas J.J, & Ellis L.D. (2023). Long and Short Duration Exposures to the Selective Serotonin Reuptake Inhibitors (SSRIs) Fluoxetine, Paroxetine and Sertraline at Environmentally Relevant Concentrations Lead to Adverse Effects on Zebrafish Behaviour and Reproduction. Toxics, 11(2), 151.
Publication 2023
Adult DNA Replication Fishes Fluoxetine Paroxetine Pharmaceutical Preparations Selective Serotonin Reuptake Inhibitors Sertraline Sulfoxide, Dimethyl Zebrafish

Top products related to «Paroxetine»

1
Paroxetine by Merck Group
Sourced in United States, Germany
Paroxetine is a laboratory product manufactured by Merck Group. It is a selective serotonin reuptake inhibitor (SSRI) used as a standard reference material in analytical testing and research applications.
2
Fluoxetine by Merck Group
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, France, Italy
Fluoxetine is a chemical compound used in laboratory settings. It is a selective serotonin reuptake inhibitor (SSRI) that affects the neurotransmitter serotonin in the brain. Fluoxetine is commonly used in research applications, but its specific core function is to modulate serotonin levels.
3
Sertraline by Merck Group
Sourced in United States
Sertraline is a laboratory equipment product manufactured by Merck Group. It is a chemical compound used in scientific research and analysis applications. The core function of Sertraline is to serve as a reference standard for analytical testing and validation procedures.
4
3h paroxetine by PerkinElmer
Sourced in United States
[3H]paroxetine is a radiolabeled compound used for research purposes. It is a tritium-labeled form of the antidepressant drug paroxetine, which is commonly used in biomedical research applications, such as receptor binding studies and pharmacokinetic investigations.
5
Citalopram by Merck Group
Sourced in United States, Switzerland, Spain
Citalopram is a pharmaceutical product manufactured by Merck Group. It is a lab equipment used for various analytical and research purposes. The core function of Citalopram is to serve as a measurement and detection tool in laboratory settings.
6
Imipramine by Merck Group
Sourced in United States, Sao Tome and Principe, Germany, United Kingdom, Japan
Imipramine is a pharmaceutical product manufactured by Merck Group for use in laboratory settings. It is a tricyclic antidepressant medication that affects the balance of certain natural substances in the brain. The core function of Imipramine is to serve as a research tool for studying the mechanisms and effects of tricyclic antidepressants in controlled laboratory environments.
7
Fluvoxamine by Merck Group
Sourced in United States
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) medication primarily used as a laboratory reagent. It is a chemical compound that functions by inhibiting the reuptake of the neurotransmitter serotonin, which can be utilized in research and development applications.
8
Paroxetine by GlaxoSmithKline
Sourced in United Kingdom
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) medication. It is a lab equipment product used in the research and development of pharmaceutical drugs.
9
3h 5 ht by PerkinElmer
Sourced in United States
[3H]5-HT is a radioactively labeled serotonin compound used for research purposes. It serves as a tool for investigating serotonin-related processes and mechanisms in various experimental settings.
10
Duloxetine by Eli Lilly
Sourced in United States
Duloxetine is a pharmaceutical compound developed and manufactured by Eli Lilly. It is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used in the treatment of various medical conditions. The core function of duloxetine is to regulate the levels of neurotransmitters in the brain, which can have therapeutic effects on conditions such as depression, anxiety, and certain types of chronic pain.

More about "Paroxetine"

Paroxetine, a selective serotonin reuptake inhibitor (SSRI), is a widely used medication for the treatment of depression, anxiety disorders, and other mental health conditions.
This antidepressant drug works by increasing the availability of the neurotransmitter serotonin in the brain, which can help improve mood and reduce symptoms.
Paroxetine, also known by its brand names Paxil and Seroxat, is generally well-tolerated, but like other medications, it may have side effects such as nausea, dry mouth, and drowsiness.
It is important to work closely with a healthcare provider when taking paroxetine to ensure the dosage is appropriate and that any potential side effects are managed effectively.
Researchers can optimize their paroxetine research by utilizing the PubCompare.ai platform, which can help identify the most reproducible and accurate protocols from the literature, preprints, and patents.
This can streamline the research process and enhance the quality of the work.
Paroxetine is similar to other SSRI medications like fluoxetine (Prozac), sertraline (Zoloft), and citalopram (Celexa), which also work by increasing serotonin levels in the brain.
To further enhance your paroxetine research, you may also want to explore related topics such as [3H]paroxetine (a radioactive derivative of paroxetine used in binding studies), imipramine (a tricyclic antidepressant), fluvoxamine (another SSRI), and [3H]5-HT (a radioactive form of the neurotransmitter serotonin).
Additionally, duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), may be of interest as it shares some similarities with paroxetine in its mechanism of action and clinical applications.